Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck’s Insomnia Agent Gaboxadol Shows Promising Phase II Results

This article was originally published in The Pink Sheet Daily

Executive Summary

The firm has highlighted the GABA-A receptor agonist as a standout result from its recent in-licensing deals.

You may also be interested in...



Merck And Lundbeck Discontinue Gaboxadol Development For Insomnia

Phase III trials for the GABA-A receptor antagonist do not support further development, the firms state.

Merck And Lundbeck Discontinue Gaboxadol Development For Insomnia

Phase III trials for the GABA-A receptor antagonist do not support further development, the firms state.

Merck Gaboxadol Submission Delayed Until Mid-2007

Merck and its partner Lundbeck will not submit an NDA for the sleep aid in the first quarter, as previously planned.

Related Content

Topics

UsernamePublicRestriction

Register

ID1132082

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel